Arcutis Biotherapeutics, Inc. (ARQT) stock
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30368% above fair value
$28.26+0.73 (+2.65%)
Close on Nov 13, 2026Market cap $3.55BP/E 128.5Yield –
Arcutis Biotherapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Arcutis Biotherapeutics's enterprise value was $3.43B on Nov 11, 2026, against $3.60B a year earlier. Over the last 5 years it ranged from $68.84M to $3.90B, with a median of $924.02M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $3.43B | +0.7% |
| 2025 | Dec 31, 2025 | $3.41B | +126.9% |
| 2024 | Dec 31, 2024 | $1.50B | +771.2% |
| 2023 | Dec 29, 2023 | $172.55M | -72.2% |
| 2022 | Dec 30, 2022 | $620.00M | -7.6% |
| 2021 | Dec 31, 2021 | $670.98M | -23.2% |
| 2020 | Dec 31, 2020 | $873.58M | – |
See a number that looks wrong?